rs1165205 — SLC17A3 SLC17A3 variant (NPT4)

Intronic variant in SLC17A3, encoding the renal apical urate efflux transporter NPT4; the A allele is associated with reduced urate secretory capacity, raising serum uric acid and increasing gout risk

See your personal result for SLC17A3

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

SLC17A3 rs1165205 — NPT4 and the Apical Urate Exit

Every day your kidneys filter and then selectively reclaim or discard uric acid as they fine-tune the serum urate setpoint. Most people know about the reabsorptive side of this equation — transporters like URAT111 URAT1
SLC22A12, encoded by the SLC22A12 gene, is the principal apical urate reabsorber in the kidney proximal tubule; it retrieves uric acid from the tubular lumen back into the bloodstream that pull uric acid back from the urine into the blood. But secretion — actively pushing uric acid from the tubular cell into the urine — is equally important, and it depends on a distinct set of apical transporters on the urine-facing surface of the proximal tubule. One of these is NPT422 NPT4
sodium-phosphate transporter 4, encoded by SLC17A3 on chromosome 6p22; an apical multispecific organic anion efflux transporter that drives uric acid out of tubular cells into the urine for excretion.

rs1165205 is an intronic variant in SLC17A3 that sits in the same gene cluster as SLC17A1 (encoding NPT1, the related apical urate efflux transporter). The A allele at this position is associated with higher serum uric acid in multiple populations and with reduced protection against gout. Because it is intronic, the variant likely influences NPT4 expression or mRNA processing rather than changing the protein directly — the secretory efficiency of the proximal tubule is tuned up or down depending on which version of the haplotype you carry.

The Mechanism

NPT4 operates as a voltage-driven organic anion efflux transporter33 voltage-driven organic anion efflux transporter
the membrane potential gradient across the apical membrane provides the driving force; an increase in extracellular potassium (simulating depolarization) enhances transport activity. It transports uric acid from the interior of the proximal tubule cell into the tubular lumen, working alongside NPT1 (SLC17A1) to provide the secretory counterbalance to URAT1-mediated reabsorption. The net direction of urate movement — secretion or reabsorption — determines whether serum urate rises or falls.

When genetic variation at the rs1165205 locus impairs this secretory arm, the reabsorption-to-secretion ratio tilts toward retention, elevating the serum urate setpoint. This mechanism also explains why loop and thiazide diuretics44 loop and thiazide diuretics
furosemide and bumetanide are competitive inhibitors of NPT4-mediated urate transport; this provides the molecular explanation for the well-known phenomenon of diuretic-induced hyperuricemia raise uric acid: they directly inhibit NPT4, reproducing the pharmacological equivalent of reduced-function genetic variants. Individuals with the A allele who also use diuretics are therefore doubly disadvantaged on urate secretory capacity.

The Evidence

rs1165205 was identified as a genome-wide significant locus for serum uric acid in the Dehghan et al. landmark GWAS published in The Lancet55 The Lancet
Dehghan A et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet, 2008, with p=3.3×10⁻²⁶ in the Framingham cohort (7,699 participants). The protective T allele was associated with OR 0.85 (95% CI 0.77–0.94, p=0.002) for gout risk in European participants. The association was not significant in African-ancestry ARIC participants, consistent with the very high A allele frequency in African populations (~88%) leaving little statistical power to detect effects.

The GWAS Catalog reports a pooled effect of approximately 0.09 unit decrease in serum urate per T allele (p=4×10⁻²⁹) across a total sample exceeding 15,000 participants. A multi-cohort analysis (n=4,492)66 multi-cohort analysis (n=4,492)
Brandstätter A et al. Sex and age interaction with genetic association of atherogenic uric acid concentrations. Atherosclerosis, 2010 confirmed the A allele as a component of the composite genetic risk score for elevated serum urate across European cohorts, with the SLC17A3 locus contributing modestly but consistently to the variance in serum uric acid levels.

Functional studies by Jutabha et al.77 Jutabha et al.
Jutabha P et al. Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate. J Biol Chem, 2010 established the biological plausibility: NPT4 is the exit route for uric acid from the proximal tubule apical membrane, and loss-of-function mutations in SLC17A3 found in hyperuricemia patients abolish urate efflux capacity in cell systems. The GWAS signal at rs1165205 is consistent with a regulatory variant that modulates this secretory capacity.

Practical Actions

Elevated urate from reduced renal secretory capacity is particularly responsive to reducing dietary purine load (since the kidneys cannot compensate by increasing secretion) and to avoiding substances that further inhibit NPT4, principally loop and thiazide diuretics. Individuals with the AA genotype on diuretics should specifically flag this to their prescriber, as the pharmacological inhibition of NPT4 compounds genetically reduced secretory capacity.

Vitamin C supplementation at 500–1,000 mg/day has modest evidence for lowering serum urate by approximately 0.5 mg/dL through competitive inhibition of renal urate reabsorption — a compensatory mechanism for reduced secretory capacity. Serum uric acid monitoring establishes the individual setpoint and guides when dietary changes need reinforcement.

Interactions

rs1165205 operates at the NPT4-mediated arm of renal urate secretion. The most clinically significant interaction is with rs2231142 in ABCG2, the breast cancer resistance protein that mediates the other major apical secretory route for urate. ABCG2 Q141K (rs2231142) reduces ABCG2 activity by approximately 50%, and when combined with reduced NPT4 capacity both secretory pathways are simultaneously compromised, producing substantially higher serum urate than either variant alone. This combination is particularly relevant in East Asian populations where both risk alleles are common.

rs1165205 is also in high linkage disequilibrium (r²=0.97) with rs1183201 in the adjacent SLC17A1 gene, which encodes NPT1 — the sibling apical urate secretory transporter. The two signals tag the same haplotype block spanning the SLC17A1–SLC17A3–SLC17A4 gene cluster. Individuals carrying risk alleles at both loci may experience additive reduction in total apical secretory capacity, though these SNPs are sufficiently correlated that both rarely appear as independent effects in the same model.

Nutrient Interactions

purine increased_need

Genotype Interpretations

What each possible genotype means for this variant.

TT Optimal NPT4 Secretory Capacity Normal

Two protective T alleles — normal urate secretion, lower baseline gout risk

You carry two copies of the protective T allele at rs1165205. This genotype is associated with the lowest serum uric acid levels at this locus — approximately 0.10–0.18 mg/dL lower than AA homozygotes. Your NPT4-mediated renal urate secretion is at the more efficient end of the population range for this gene, supporting effective urate clearance. About 23% of Europeans share this genotype; it is uncommon in East Asian and African populations where the A allele predominates.

This result does not mean you are immune to gout — many other factors (other urate transporter variants, diet, alcohol, diuretic use, kidney function, and sex) also determine your individual urate level and gout risk.

AT Intermediate NPT4 Function Intermediate

One A risk allele — modestly elevated serum urate setpoint, mild gout risk increase

The rs1165205 A allele tags a haplotype in the SLC17A1–SLC17A3 gene cluster on chromosome 6 that is associated with reduced NPT4 (and possibly NPT1) secretory activity at the renal proximal tubule apical membrane. With one A copy and one T copy, your secretory capacity falls between the two homozygous states. In the Dehghan et al. 2008 GWAS (Framingham and Rotterdam cohorts), the protective T allele was associated with an OR of 0.85 for gout — meaning heterozygotes have intermediate risk relative to TT and AA homozygotes.

The moderate risk is most relevant when other urate-raising factors co-exist: diuretic use (which pharmacologically inhibits NPT4), high dietary purine intake, concurrent ABCG2 risk alleles (rs2231142), obesity, or alcohol use. Under these conditions, even a modest reduction in secretory capacity can tip serum urate above the 6.0 mg/dL threshold for monosodium urate crystal formation.

AA Reduced NPT4 Secretory Capacity High Risk

Two A risk alleles — elevated serum urate baseline, meaningfully increased gout risk

The AA genotype at rs1165205 places you on the reduced-secretory-capacity haplotype of the SLC17A1–SLC17A3 gene cluster at both copies. NPT4 mediates urate efflux from the renal proximal tubule apical membrane into the urine — when this pathway is less efficient, uric acid is retained in the bloodstream at a higher setpoint. The variant is intronic and likely acts by modulating SLC17A3 expression or processing rather than altering the NPT4 protein directly.

The effect is compounded by agents that pharmacologically inhibit NPT4 — specifically loop diuretics (furosemide, bumetanide) and thiazide diuretics, which are competitive inhibitors of this transporter. Diuretic use in AA homozygotes can push serum urate substantially above the 6.0 mg/dL threshold for crystal formation. Similarly, concurrent ABCG2 risk alleles at rs2231142 remove the second major apical secretory route for urate, leaving renal excretion dependent on reabsorptive modulation alone.

The A allele frequency varies dramatically by ancestry — reaching 86–88% in East Asian and African populations, meaning AA homozygotes are the majority genotype in these groups. Despite the high frequency, gout remains a recognisable clinical phenotype when multiple urate-raising factors converge, making genetic forewarning valuable.